Mycenax Biotech Financial Flexibility Index
Mycenax Biotech financial flexibility index. Mycenax Biotech (4726) has a Financial Flexibility Index of -0.02x as of September 2025. Free cash flow of NT$-25.73 Million (operating CF NT$-50.35 Million minus capex NT$24.62 Million) represents 0% of total liabilities (NT$1.69 Billion). See 4726 FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Financial Flexibility Index of Mycenax Biotech (2017–2024)
Financial flexibility index of Mycenax Biotech from 2017 to 2024. Historical Financial Flexibility Index trend for Mycenax Biotech across 8 annual periods. Check Mycenax Biotech (4726) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Mycenax Biotech Financial Flexibility Index by Year (2017–2024)
Mycenax Biotech financial flexibility index by year from 2017 to 2024. Year-by-year free cash flow to debt coverage for Mycenax Biotech. For the full cash flow conversion analysis, see Mycenax Biotech cash conversion from operations.
| Year | Flexibility Index | Free Cash Flow (TWD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2024 | 0.10x | NT$138.83 Million | NT$-191.68 Million | NT$1.34 Billion | ▼ -17.9% |
| 2023 | 0.13x | NT$166.42 Million | NT$-131.18 Million | NT$1.32 Billion | ▼ -64.5% |
| 2022 | 0.35x | NT$476.75 Million | NT$-150.19 Million | NT$1.35 Billion | ▼ -54.2% |
| 2021 | 0.77x | NT$951.86 Million | NT$-146.23 Million | NT$1.23 Billion | ▼ -3.8% |
| 2020 | 0.80x | NT$434.39 Million | NT$174.17 Million | NT$540.89 Million | ▲ +561.3% |
| 2019 | 0.12x | NT$37.17 Million | NT$-140.74 Million | NT$306.04 Million | ▲ +141.6% |
| 2018 | -0.29x | NT$-61.79 Million | NT$-180.27 Million | NT$211.70 Million | ▼ -207.3% |
| 2017 | 0.27x | NT$45.96 Million | NT$-45.55 Million | NT$168.93 Million | — |